Overview

A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Status:
Recruiting
Trial end date:
2026-12-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, single arm, open label phase II clinical study in China. This study will evaluate the efficacy and safety of ABSK021 (Pimicotinib) in the treatment of patients with cGvHD who failed first-line therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Abbisko Therapeutics Co, Ltd